HEPWIN^®(entecavir)VIATRISHK Reg. No. HK-68889 (28 Oct, 2025)

Composition:⁴

• Each film-coated tablet contains entecavir monohydrate equivalent to 0.5 mg entecavir

Indication:⁴

• Indicated for the treatment of chronic hepatitis B virus (HBV) infection in adults with:  

• compensated liver disease and evidence of active viral replication, persistently elevated serum alanine aminotransferase (ALT) levels and histological evidence of active inflammation and/or fibrosis

• decompensated liver disease

• For both compensated and decompensated liver disease, this indication is based on clinical trial data in nucleoside naive patients with HBeAg positive and HBeAg negative HBV infection

• Also indicated for the treatment of chronic HBV infection in nucleoside naive pediatric patients from 2 to <18 years of age with compensated liver disease who have evidence of active viral replication and persistently elevated serum ALT levels, or histological evidence of moderate to severe inflammation and/or fibrosis

References4. EMA. Summary of Product Characteristics. Available from: https://www.ema.europa.eu/en/documents/product-information/entecavir-viatris-epar-product-information_en.pdf. [Accessed 18 November 2025].